⚕ GetRetatrutide.ca

Retatrutide: the triple-agonist weight loss treatment in clinical trials

Evidence-based information about retatrutide (LY3437943) for Canadians — how it works, what the trials show, and legitimate access pathways.

How it works Clinical trial data Access in Canada Get notified →
~24%
Mean weight reduction at 48 weeks
Phase 2 trial, highest dose group
3
Receptors targeted: GIP, GLP‑1, glucagon
vs. 1–2 in existing treatments
Phase 3
Current trial stage — TRIUMPH program
Not yet approved for any use

What makes retatrutide different

Most weight loss medications target one receptor. Tirzepatide (Mounjaro®) targets two. Retatrutide is the first to reach late-stage trials targeting three receptors simultaneously — GIP, GLP-1, and glucagon.

GLP-1 activation suppresses appetite. GIP enhances insulin sensitivity and fat metabolism. Glucagon — the third target — increases energy expenditure. The hypothesis: hitting all three pathways produces greater weight loss than targeting any one or two alone.

Phase 2 results, published in the New England Journal of Medicine (June 2023), support this: participants receiving the highest dose lost an average of ~24% of body weight over 48 weeks. Phase 3 TRIUMPH trials are now underway to confirm these findings in larger populations, with the first Phase 3 results reporting up to 30.3% weight loss (Lilly press release, May 2026).

Important Retatrutide is an investigational pharmaceutical, not a supplement, research chemical, or over-the-counter product. Anyone selling "retatrutide" outside of approved clinical channels is offering an unregulated substance with unknown purity and safety.

Full explanation →

How retatrutide compares

Retatrutide vs. tirzepatide vs. semaglutide. Cross-trial comparisons have limitations — these were different studies with different populations.

RetatrutideTirzepatideSemaglutide
ReceptorsGIP + GLP-1 + GlucagonGIP + GLP-1GLP-1 only
TypeTriple agonistDual agonistSingle agonist
Weight loss~24% (48 wks, Ph 2)~21% (72 wks, SURMOUNT-1)~15% (68 wks, STEP-1)
In Canada?Clinical trials onlyApproved (Mounjaro®)Approved (Wegovy®)
DeveloperEli LillyEli LillyNovo Nordisk

Full comparison →

How Canadians can access retatrutide

Retatrutide is not sold in any pharmacy. Current legitimate pathways:

  1. Clinical trials: Several Canadian sites are recruiting for the TRIUMPH program. Participation is free, with medical monitoring included.
  2. Health Canada Special Access Programme (SAP): Physicians can request access for individual patients who meet specific criteria. Requires manufacturer cooperation.
  3. Future approval: If Phase 3 results are positive, Eli Lilly is expected to seek Health Canada approval, potentially 2026–2027.
Warning: Products marketed as "retatrutide for research" online are unregulated. Their contents, purity, and sterility are unknown. This site does not facilitate or endorse purchases of such products.

Explore access pathways →

Frequently asked questions

What is retatrutide?
Retatrutide (LY3437943) is an investigational once-weekly injectable peptide that targets GIP, GLP-1, and glucagon receptors — a triple agonist. Currently in Phase 3 clinical trials (TRIUMPH program). Not yet approved by Health Canada or the FDA.
How does it compare to other weight loss drugs?
Retatrutide targets three receptors versus tirzepatide's two (GIP + GLP-1) and semaglutide's one (GLP-1). Phase 2 data showed mean weight reduction up to ~24% at 48 weeks. Direct head-to-head trials are ongoing as part of TRIUMPH-5.
Is retatrutide available in Canada?
No — retatrutide is not commercially available anywhere. It is accessible only through clinical trials or Health Canada's Special Access Programme for individual patients. Products sold online as "retatrutide" are unregulated and potentially dangerous.
What are the side effects?
Most common in trials: nausea, diarrhea, vomiting, and decreased appetite — generally mild to moderate and improving over time. Full safety data is being collected in ongoing Phase 3 trials. See our safety page for details.
When might it be approved?
No confirmed date. If Phase 3 results are positive, regulatory submission could occur in 2026–2027. Health Canada review timelines vary. Approval is not guaranteed — it depends on the strength of the clinical data.
Medical Disclaimer: This website provides educational information only. It does not provide medical advice, diagnosis, or treatment recommendations. Retatrutide is an investigational medication not approved by Health Canada, the FDA, or any regulatory body. Always consult a licensed healthcare provider. Do not purchase unregulated products marketed as retatrutide.